NEW YORK — UK-based reagent provider Aptamer Group said on Thursday that it has partnered with Mologic to develop a rapid aptamer-based SARS-CoV-2 antigen test.
Aptamer is developing a rapid lateral flow assay, called AptaDx, that is designed to rapidly detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. The company said that clinical validation of the test to support CE marking is underway at the Integrated COVID Hub North East in Newcastle.
Under the terms of the alliance, Mologic will help Aptamer develop the test and provide manufacturing capacity for a final product. Additional terms were not disclosed.
Aptamer said that it is also in discussions with other manufacturers in order to be able to provide several million tests a month.
Last month, UK-based Mologic signed an agreement to help develop, manufacture, and distribute SARS-CoV-2 tests with Avacta.